Payment overview · 2025
General Payments
$589.07
29 reported records · 14 companies
Healthcare provider profile · identity verified
Laurel M Tucker, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HOUSTON, TX · NPI 1528063633
Verified facts
What the public records show
CMS Open Payments records show Laurel M Tucker, M.D. received $589.07 in general payments during 2025 across 29 reported records.
Novo Nordisk Inc accounted for 21.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $123.47 | 21.0% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $75.32 | 12.8% | 5 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $68.94 | 11.7% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $67.92 | 11.5% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $47.68 | 8.1% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $32.77 | 5.6% | 1 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $32.46 | 5.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.44 | 5.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.34 | 3.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.83 | 3.4% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $19.10 | 3.2% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $17.51 | 3.0% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.68 | 2.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.61 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $589.07 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $100.84 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $73.76 | 3 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $68.94 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $47.68 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $44.11 | 3 | 2025 |
Source payment records
|
|||||
| LAGEVRIO Normalized: lagevrio |
Drug | Merck Sharp & Dohme LLC | $38.10 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $32.77 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $32.77 | 1 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $32.46 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.44 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.44 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $31.21 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $29.82 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $29.82 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.63 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.34 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.34 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.34 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.83 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.83 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.61 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
18 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 308 | 93 |
| Atorvastatin Calcium | Atorvastatin Calcium | 242 | 83 |
| Lisinopril | Lisinopril | 209 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 153 | 50 |
| Omeprazole | Omeprazole | 137 | 44 |
| Amlodipine Besylate | Amlodipine Besylate | 116 | 39 |
| Synthroid | Levothyroxine Sodium | 116 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 103 | 37 |
| Losartan Potassium | Losartan Potassium | 96 | 32 |
| Montelukast Sodium | Montelukast Sodium | 91 | 26 |
| Metformin Hcl | Metformin Hcl | 88 | 29 |
| Sertraline Hcl | Sertraline Hcl | 88 | 19 |
| Simvastatin | Simvastatin | 88 | 29 |
| Alprazolam | Alprazolam | 87 | 21 |
| Clonazepam | Clonazepam | 83 | 28 |
| Azelastine Hcl | Azelastine Hcl | 82 | 51 |
| Escitalopram Oxalate | Escitalopram Oxalate | 82 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 32 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 60 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 57 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 19 |
| Ibandronate Sodium | Ibandronate Sodium | 38 | 13 |
| Alendronate Sodium | Alendronate Sodium | 37 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 36 | 17 |
| Furosemide | Furosemide | 36 | 12 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 36 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 36 | 15 |
| Valacyclovir | Valacyclovir Hcl | 35 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 34 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 34 | 11 |
| Gabapentin | Gabapentin | 33 | 12 |
| Meloxicam | Meloxicam | 32 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 32 | 11 |
| Tramadol Hcl | Tramadol Hcl | 32 | suppressed |
| Azithromycin | Azithromycin | 30 | 29 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 24 |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Lorazepam | Lorazepam | 29 | suppressed |
| Estradiol | Estradiol | 28 | 11 |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | 11 |
| Cefuroxime | Cefuroxime Axetil | 24 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Allopurinol | Allopurinol | 21 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 18 |
| Atenolol | Atenolol | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 18 | 13 |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Potassium Chloride | Potassium Chloride | 14 | suppressed |
| Progesterone | Progesterone, Micronized | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Zafirlukast | Zafirlukast | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $589.07 · 29 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, APLENZIN, AREXVY, Azstarys, CAPVAXIVE, COMIRNATY, CONTRAVE, Cologuard Collection Kit, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, Fluad, Flucelvax, GARDASIL 9, INSPIRE, LAGEVRIO, MOUNJARO, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, TRELEGY ELLIPTA, Wegovy, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error